Invitae Corp (NVTAQ)
OTCMKTS: NVTAQ · Delayed Price · USD
0.0005
-0.0085 (-94.44%)
Apr 26, 2024, 3:58 PM EDT - Market closed
Invitae Revenue
Invitae had revenue of $481.58M in the twelve months ending September 30, 2023, down -7.38% year-over-year. Revenue in the quarter ending September 30, 2023 was $121.24M, a -9.21% decrease year-over-year. In the year 2022, Invitae had annual revenue of $516.30M with 12.13% growth.
Revenue (ttm)
$481.58M
Revenue Growth
-7.38%
P/S Ratio
0.00
Revenue / Employee
$283,284
Employees
1,700
Market Cap
143.25K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 516.30M | 55.85M | 12.13% |
Dec 31, 2021 | 460.45M | 180.85M | 64.68% |
Dec 31, 2020 | 279.60M | 62.77M | 28.95% |
Dec 31, 2019 | 216.82M | 69.13M | 46.80% |
Dec 31, 2018 | 147.70M | 79.48M | 116.50% |
Dec 31, 2017 | 68.22M | 43.17M | 172.36% |
Dec 31, 2016 | 25.05M | 16.67M | 198.97% |
Dec 31, 2015 | 8.38M | 6.77M | 422.32% |
Dec 31, 2014 | 1.60M | 1.46M | 983.78% |
Dec 31, 2013 | 148.00K | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
NVTAQ News
- 3 days ago - Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln - Reuters
- 3 days ago - Labcorp Announces Winning Bid for Select Assets of Invitae - PRNewsWire
- 3 days ago - Invitae Enters into Agreement with Labcorp for Sale of Business - PRNewsWire
- 5 days ago - Invitae Publishes its Environmental, Social and Governance (ESG) Report - PRNewsWire
- 17 days ago - Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance - PRNewsWire
- 6 weeks ago - Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification - PRNewsWire
- 7 weeks ago - Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results - PRNewsWire
- 7 weeks ago - Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting - PRNewsWire